Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study

Study information

Needs review Marked as Needs review by Fatima on 2023/03/30
Quality issues

study design

prospective cohort

Citation

PMID PubMed identifier for scientific articles.

32925716

DOI Digital object identifier for electronic documents.

10.1097/MD.0000000000021788

URI

https://pubmed.ncbi.nlm.nih.gov/32925716/

Authors

Li L, Ye J

Journal

Medicine

Year

2020

Hepatocellular carcinoma (HCC) is one of the most common neoplasms encountered, and its incidence is increasing worldwide. In this study, we explored the characteristics of gut microbiota in patients with primary hepatocellular carcinoma in advanced stage who received immune checkpoint inhibitors (ICIs) based on a large population with hepatitis B virus infection. An initial cohort of 65 patients with metastatic melanoma were included in this study. All patients were treated with ICIs at Fujian provincial geriatric hospital between August 2016 and June 2018. The 16S rDNA V4 region was amplified by Polymerase chain reaction and sequenced on the MiSeq platform. We found that the diversities of the gut microbiota in HCC who received ICIs were obviously increased. Negative feedback, which is controlled by interplay between microbial metabolic activities and host pathways, is thought to promote high bacterial diversity. We focused on the Faecalibacterium genus in response group, and Bacteroidales order in non-response group, and stratified patients into high versus low categories based on the median relative abundance of these taxa in the gut microbiome. Patients with high Faecalibacterium abundance had a significantly prolonged PFS versus those with a low abundance. Conversely, patients with a high abundance of Bacteroidales had a shortened progressive free survival compared to those with a low abundance. In summary, the present study examined the oral and gut microbiome of HCC patients undergoing immune checkpoint inhibitors immunotherapy. Significant differences were observed in the diversity and composition of the patient gut microbiome of responders versus non-responders.

Experiment 1

Edit History Delete

Mark reviewed

Your review change was submittedDuplicate this Experiment Add a new Signature

Needs review Marked as Needs review by Fatima on 2023-3-30

Curated date: 2022/07/15

Curator: Sharmilac

Revision editor(s): Sharmilac, Fatima, LGeistlinger, WikiWorks

Subjects

Location of subjects: China

Host species Species from which microbiome was sampled (if applicable): Homo sapiens

Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology: Buccal mucosa , Feces Buccal mucosa,Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology: response to immunochemotherapy response to immunochemotherapy

Group 0 name Corresponds to the control (unexposed) group for case-control studies: Non-responders
Group 1 name Corresponds to the case (exposed) group for case-control studies: Responders
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group: Patients who were diagnosed with uveal HCC or who received ICIs in combination with targeted agents or with adoptive T cell transfer therapy

Lab analysis

Sequencing type: 16S

16S variable region One or more hypervariable region(s) of the bacterial 16S gene: V4

Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance: Illumina

Statistical Analysis

Statistical test: LEfSe

Significance threshold p-value or FDR threshold used for differential abundance testing (if any): 0.05

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness: increased

Signature 1

Edit History Delete

Flag for review

Your review change was submitted

Reviewed Marked as Reviewed by Fatima on 2022/08/17

Curated date: 2022/07/15

Curator: Sharmilac

Revision editor(s): Sharmilac, Fatima

Source: Figure 1b

Description: Compositional differences in the gut microbiome are associated with responses to anti-PD-1 immunotherapy.

Abundance in Group 1: increased abundance in Responders

NCBI	Quality Control	Links
Clostridia
Faecalibacterium
Faecalibacterium prausnitzii
Bacillota
Micrococcaceae
Mollicutes
Oscillospiraceae
Peptoniphilus
Phascolarctobacterium
Phascolarctobacterium faecium
Porphyromonas pasteri
Rothia
Ruminiclostridium hungatei
Ruminococcus
Ruminococcus bromii
Veillonellaceae
Eubacteriales

Revision editor(s): Sharmilac, Fatima

Signature 2

Edit History Delete

Flag for review

Your review change was submitted

Reviewed Marked as Reviewed by Fatima on 2022/08/17

Curated date: 2022/07/21

Curator: Sharmilac

Revision editor(s): Sharmilac, Fatima

Source: Figure 1b

Description: Compositional differences in the gut microbiome are associated with responses to anti-PD-1 immunotherapy.

Abundance in Group 1: decreased abundance in Responders

NCBI	Quality Control	Links
Bacteroidales
Bacteroidota
Bacteroidia
Collinsella stercoris
Bacteroides mediterraneensis
Oleidesulfovibrio alaskensis
Prevotella histicola
Gardnerella vaginalis
Gardnerella

Revision editor(s): Sharmilac, Fatima